Plain-English translation of NCT07452198 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether — a new treatment — works better than a standard three-drug combination (, , and ) for patients with multiple myeloma that has come back or stopped responding to earlier treatments. About 358 people will be randomly assigned to receive either the new medication or the standard combination. Researchers want to see which approach helps patients live longer and have better control of their cancer.
Multiple myeloma often comes back or becomes resistant to initial treatments, leaving patients with limited options. This trial exists to find out whether this new treatment might offer patients a more effective choice than currently available standard therapies.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new injectable medication (GR1803) or the standard three-drug combination therapy. Your doctor will give you the treatment according to a set schedule, and you'll have regular clinic visits for blood tests and check-ups to monitor how well the treatment is working and to watch for any side effects. The study will continue until your disease progresses or you experience unmanageable side effects, with follow-up visits to track your long-term response.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China